What's in Alexion Pharmaceuticals, Inc.'s pipeline?

Alexion Pharmaceuticals, Inc. has 49 drugs in our index: 1 marketed, 0 filed, 5 in Phase 3, 8 in Phase 2, 35 in Phase 1.

Which companies overlap with Alexion Pharmaceuticals, Inc.'s portfolio?

Top competitors by shared drug class: Sanofi, CSL Behring, Hoffmann-La Roche, Pfizer Inc., Arbeitsgemeinschaft medikamentoese Tumortherapie.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/alexion-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Alexion Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Alexion Pharmaceuticals, Inc. pipeline: 1 marketed, 0 filed, 5 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 5 Phase 3 8 Phase 2 35 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Ultomiris	Ultomiris	marketed		Complement C5	Other
ALXN1850	ALXN1850	phase 3	Complement C3 inhibitor	Complement C3	Nephrology / Immunology
ALXN2060	ALXN2060	phase 3	Complement C3 inhibitor	Complement C3	Immunology / Hematology
C5 Inhibitor	C5 Inhibitor	phase 3	Complement C5 inhibitor	C5	Immunology
CAEL-101	CAEL-101	phase 3	Transthyretin (TTR) stabilizer	Transthyretin (TTR)	Rare Disease / Amyloidosis
pexelizumab in conjunction with CABG	pexelizumab in conjunction with CABG	phase 3	Monoclonal antibody	Complement component 5 (C5)	Cardiovascular

Therapeutic area mix

Rare Disease · 2
Cardiovascular · 1
Genetics and Rare Diseases · 1
Immunology · 1
Immunology / Hematology · 1
Nephrology / Immunology · 1
Neurology · 1
Other · 1
Autoimmune diseases · 1
Rare Disease / Amyloidosis · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sanofi · 2 shared drug classes
CSL Behring · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
Pfizer Inc. · 2 shared drug classes
Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Aldeyra Therapeutics, Inc. · 1 shared drug class
Apellis Pharmaceuticals, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Alexion Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Alexion Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alexion-pharmaceuticals-inc. Accessed 2026-05-16.